HomeMarket NewsNovo Nordisk Shines with Q4 Earnings and Long-Term Vision

Novo Nordisk Shines with Q4 Earnings and Long-Term Vision

Actionable Trade Ideas

always free

Top view of calculator,pen,sand clock,plant and paper written with Shareholder on wooden background.Business and finance concept.

Mohamad Faizal Bin Ramli

Numerous Highlights from Q4 Earnings

  • Novo Nordisk has reported a Q4 GAAP EPS of DKK 4.91.
  • The revenue stands at an impressive DKK 65.86 billion, marking a 37.0% Y/Y growth.
  • Sales within Diabetes and Obesity care have seen significant strides, increasing by 38% in Danish kroner to DKK 215.1 billion (42% at CER).

Outlook Initiatives for 2024

The future outlook of Novo Nordisk encompasses ambitious targets for 2024, showcasing a strong stance for continued growth and innovation.

  • Sales growth at CER is projected to be in the range of 18% to 26% as reported, slightly lower than at CER.
  • Operating profit growth at CER is estimated to be between 21% to 29% as reported, further showing promising prospects.
  • The financial items (net) gain is expected to reach around DKK 1.3 billion, indicating a robust financial position.
  • Additionally, the effective tax rate is forecasted to be within the range of 19% to 21%, reflecting prudent financial management.
  • Capital expenditure (PP&E) is to be around DKK 45 billion, a significant investment in future growth and sustainability.
  • Furthermore, Novo Nordisk anticipates free cash flow (excluding impact from business development) in the range of DKK 64-74 billion, demonstrating strong financial performance.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.